Dr Nick Cunniffe leads the Cambridge Clinical Remyelination Research Group, a team dedicated to developing treatments that can reverse damage in MS.

Give now to support Support research work in Cambridge to repair myelin and preserve function in multiple sclerosis.

MS is a lifelong neurological condition affecting over 150,000 people in the UK, causing disability through the loss of myelin - the protective sheath around nerve fibres. This damage disrupts communication within the brain and spinal cord, leading to physical, cognitive, and visual impairments.

The group’s research focuses on remyelination: repairing this damaged myelin to restore nerve function and prevent or reverse disability. In Cambridge, the team is running innovative clinical trials to test promising drugs that enhance the brain’s natural repair processes. They are also developing advanced imaging and blood-based tests to measure remyelination more precisely and efficiently. These approaches will help identify which treatments work, for whom, and at what time.

Supporting this research will accelerate the development of therapies that could delay, prevent, or reverse disability associated with multiple sclerosis.

Next steps

You can support this research by giving a gift online now or to discuss your philanthropic objectives, please contact:

Make a gift now

Make a gift now to support by credit or debit card, or set up a direct debit:

Give now

Or, find out about other ways to give.

Head of Development, Brain and Mind Health

Belen Tejada-Romero
belen.tejadaromero@admin.cam.ac.uk

Leave a gift in your will

Alice Macek
legacies@philanthropy.cam.ac.uk

Find out more

This opportunity is part of

The Cambridge Clinical Multiple Sclerosis Research Group

The Cambridge Clinical Multiple Sclerosis Research Group, based at the University of Cambridge, brings together clinicians and researchers with a single shared objective: to prevent and reverse disability in multiple sclerosis, neuromyelitis optica and related conditions.